Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Lizhi

BondBloxx Bloomberg One Year Target Duration US Treasury ETF

These three fast-going stocks are raising temperatures even during the depths of winter.

3 Hot Stocks to Watch In February

The stock price of Tilray Inc (NASDAQ: TLRY) is trading at over 20% pre-market as of 6:13 AM ET. This is why it happened.

TLRY Stock Price Increases Over 20% Pre-Market: Why It Happened

The company's organic medicine should become available within weeks.

Tilray Strikes Deal to Export Medical Marijuana to the U.K.

Aurora Cannabis

Canopy Growth

Cronos Group

MedMen Enterprises Inc.

Cannabis industry stocks soared on Tuesday as industry leaders made groovy predictions about their financial prospects and marijuana legalization in Washington. Shares in Canadian grower Tilray finished up more than 40 percent on Tuesday after Chief executive Brendan Kennedy mused to Bloomberg Television that he now expects more state and possibly a federal legalization within.

Pot stocks soar on renewed hopes of legalization

Cisco Systems

Lyft

Twitter

With Tilray (TLRY) +44% and Canopy (CGC) +12% on the day, the Nasdaq and Russell 2000 managed to climb to fresh all-time highs Tuesday.

Pot Stocks Take Markets Higher; Plus Beats for Cisco, Twitter, Lyft

Tilray's agreement with Grow Pharma to import and distribute medical cannabis products in the United Kingdom is just the latest example of how investors are embracing pot stocks.

Any News Is Good News for Pot Stock Investors. Tilray Shares Are Up More Than 35%.

Grow Pharma said it has struck a deal with cannabis and pharma giant Tilray (NASDAQ:TLRY) to import and distribute the latter's medical cannabis products in the UK. Patients will have access to the products by obtaining prescriptions privately or via the National Health Service (NHS) and Tilray expects to have them available by March this year.

Grow Pharma set to distribute Tilray's medical cannabis products in the UK

Aphria

OrganiGram Holdings Inc.

Investors in the Canadian pot growers are seeing potential outside the Great White North.

Why Tilray, Aphria, and OrganiGram Stocks Are All Soaring Today

Good news for the cannabis industry is standing out on a calm market day.

Why Pot Stocks Are Soaring Again in Tuesday's Stock Market

Tilray stock soared after an agreement with Grow Pharma to import and distribute its medical cannabis products in the United Kingdom.

Tilray shares surge nearly 40% on deal to import and distribute medical cannabis in the UK

Tilray Inc. (NASDAQ: TLRY) shares jumped on Tuesday after the company announced that it would be expanding its operations across the pond.

Tilray Expands Cannabis Empire Across the Pond

SNDL Inc.

Cannabis stocks like SNDL, CGC and TLRY stock are on the move Monday after Tilray announced a medical marijuana distribution deal. The post Cannabis Stocks: Why TLRY, CGC, APHA, ACB and SNDL Are Climbing Today appeared first on InvestorPlace.

Cannabis Stocks: Why TLRY, CGC, APHA, ACB and SNDL Are Climbing Today

Tilray stock soared by more than 20% early Tuesday after the company announced a deal with Grow Pharma to import and distribute its medical cannabis in the UK. Patients in the UK will be able to obtain Tilray's cannabis through prescriptions from the country's National Health Service or from private practices.

Tilray jumps 20% on deal with Grow Pharma to distribute medical cannabis in the UK (TLRY)

Tilray stock headed for its second straight day of explosive gains Tuesday after the pot grower announced a deal to ship medical marijuana to Britain. The Canadian company's shares surged about 20 percent in premarket trading to $36.25 as of 8:02 a.m.

Tilray stock surges for second day after UK cannabis deal

Zynga

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Here's Why Tilray, Aphria, Zynga Are Moving

GrowGeneration Corp

The monster combination of Aphria and Tilray is a loadstone that has sparked a faith-based move by investors into the cannabis space over recent weeks. That has been helped by continued aggressive speculator involvement in the equities market more generally.

Pot Stock Outperformance and How to Play It (OTC US: GRWG) (OTC US: MEDH) (NASDAQ: TLRY)

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has established an agreement with Grow Pharma to import and distribute Tilray's medical cannabis products into the United Kingdom (UK). This agreement allows Tilray to provide authorized UK patients in need with a locally maintained supply of medical cannabis solutions. Tilray expects to have a range of GMP-certified, medica

Tilray® Announces Agreement with Grow Pharma to Import and Distribute Medical Cannabis Products in the United Kingdom

Cannabis companies have seen their share prices rise significantly this year as U.S. lawmakers look set to tackle federal marijuana reform measures. What Happened: Shares of Tilray Inc. (NASDAQ:TLRY) have gained over 250% since the start of January.

Is Tilray Set For Another Short Squeeze?

HEXO Corp

The U.S. Cold War against cannabis is rapidly thawing.

Why a Slew of Marijuana Stocks Blasted Higher Today

Since the merger was announced last December, Tilray shares have detached from the merger price and are trading at a ~30% premium. Merger arbitrage is best played through a paired trade (long Aphria and short Tilray); market prices indicate borrowing costs of shorting Tilray is much higher than the ~30% merger discount.

Tilray/Aphria: The 30% Merger Arbitrage Is Tough To Play

Amplify Alternative Harvest ETF

With Democrats in both chambers of Congress and a Biden White House, federal legalization may be close to reality.

Op-ed: Cannabis investors are about to ride a legislative tailwind in Washington

The pot producer was swept along by a tide of good news.

Why Tilray Surged 119.1% in January

Let's take a look at a couple of cannabis stocks that are off to a hot start in February.

2 Cannabis Stocks off to a Hot Start in February

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech ("Worldpharma"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the

Tilray® Exports First Shipment of Medical Cannabis to Spain

Hint: it has little to do with weed production.

News for Tilray Brands Stock (TLRY)